imatinib mesylate has been researched along with Astrocytoma, Grade IV in 50 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (48.00) | 29.6817 |
| 2010's | 19 (38.00) | 24.3611 |
| 2020's | 7 (14.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, R; Biagioni, S; Brancaccio, D; Bufano, M; Ceramella, J; Coluccia, A; Coluccia, AML; Da Pozzo, E; Hamel, E; Iacopetta, D; La Regina, G; Liu, T; Martini, C; Nalli, M; Orlando, V; Puxeddu, M; Sebastiani, J; Shen, H; Silvestri, R; Sinicropi, MS; Tremolanti, C | 1 |
| Abdullaev, Z; Aboud, O; Aldape, K; Antony, R; Armstrong, TS; Boris, L; Butler, M; Camphausen, K; Chou, HC; Gilbert, MR; Holdhoff, M; Kamson, D; Kaplan, R; Khan, J; Kim, O; Mackey, M; Merchant, M; Pack, S; Pang, Y; Quezado, M; Ranjan, A; Sindiri, S; Song, YK; Wei, JS; Wen, X; Wu, J; Xi, L; Yu, G; Zaghloul, K | 1 |
| Detroja, R; Flueh, C; Frenkel-Morgenstern, M; Glass, R; Gorohovski, A; Har-Nof, S; Kanner, AA; Kurtz, M; Laviv, Y; Levy-Barda, A; Palande, V; Perez, S; Raviv Shay, D; Siegal, T; Viviana Karpuj, M | 1 |
| Doytchinova, I; Iwanov, I; Momekov, G; Montesi, M; Naydenova, E; Panseri, S; Rossi, A; Sargsyan, A | 1 |
| Giordano, FA; Grimm, M; Groden, C; Hochhaus, A; Hofheinz, R; Sautter, L; Schmieder, K; Tuettenberg, J; Vajkoczy, P; Wenz, F | 1 |
| Cheng, H; Lau, CC; Nan, X; Qiu, B; Sheng, J; Wang, J; Wong, STC; Yin, Z; Yustein, JT; Zhao, H | 1 |
| Cardoso, AM; Cunha, PP; Jurado, AS; Marante, T; Morais, CM; Pedroso de Lima, MC; Pena, F | 1 |
| Andersson, C; Bergqvist, M; Blomquist, E; Ekman, S; Gullbo, J; Isaksson, A; Johansson, F; Kultima, HG; Lennartsson, J; Sooman, L | 1 |
| Classen, CF; Krohn, M; Linnebacher, M; Mullins, CS; Schneider, B; Stockhammer, F | 1 |
| Bai, Y; Chang, Z; Guo, H; Liao, H; Liu, T; Liu, Y; Qiu, S; Wang, X; Yan, X | 1 |
| Klagsbrun, M; Nakayama, H; Procaccia, V; Shimizu, A | 1 |
| Becq, J; Bentley, D; Benz, SC; Birkbak, NJ; Brada, M; Dietrich, PY; Eklund, AC; Favero, F; Forshew, T; Gerlinger, M; Grocok, RJ; Gutteridge, A; Humphray, S; Kingsbury, Z; McGranahan, N; Peden, JF; Roger, S; Rowan, A; Salm, M; Sanborn, JZ; Spencer-Dene, B; Stamp, G; Swanton, C; Szallasi, Z | 1 |
| Bai, Y; Guo, H; Huang, L; Liao, H; Liu, T; Liu, Y; Qiu, S; Wang, X; Xu, N; Yan, X; Zheng, L | 1 |
| Amin, HM; Chandra, J; Irwin, ME; Johnson, BP; Manshouri, R | 1 |
| Heath, JR; Johnson, H; Kravchenko-Balasha, N; Levine, RD; White, FM | 1 |
| Ahmad, FJ; Khan, AM; Panda, AK; Talegaonkar, S | 1 |
| Barrett, A; Brandner, S; Evans, IM; Frankel, P; Frolov, A; Li, N; Lockwood, N; Paliashvili, K; Sidlauskas, K; Zachary, IC | 1 |
| Aktas, E; Aras, Y; Bilir, A; Erguven, M; Yazihan, N | 1 |
| Jain, M; Kesari, S; Kung, AL; Lemieux, ME; Tran, MA; Wright, RD; Zawel, L; Ziegler, DS | 1 |
| Amariglio, N; Gal, H; Givol, D; Kanner, AA; Lithwick-Yanai, G; Pandi, G; Ram, Z; Rechavi, G | 1 |
| Bornhäuser, M; Dresemann, G; Ehninger, G; Hosius, C; Illmer, T; Nikolova, Z; Prondzinsky, R; Pursche, S; Said, SM; Schleyer, E; von Bonin, M; Wang, Y | 1 |
| Fink, GR; Galldiks, N; Kracht, LW; Schroeter, M; Ullrich, R | 1 |
| Beumer, JH; Desjardins, A; Egorin, MJ; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; Reardon, DA; Salvado, AJ; Vredenburgh, JJ | 1 |
| Facoetti, A; Mazzini, G; Nano, R; Ranza, E | 1 |
| Dresemann, G; Engel, E; Fluge, O; Heinrich, B; Hosius, C; Karup-Hansen, A; Krex, D; Mayer-Steinacker, R; Mehdorn, M; Nikolova, Z; Nowak, A; Olver, IN; Parker, R; Rosenthal, MA; Schleyer, E; Sieder, C; Sorenson, G; Steinbach, JP; Wagner, W; Wedding, U; Weller, M | 1 |
| Bonekamp, D; Cao, B; Gallia, GL; Grossman, SA; Hann, CL; Holdhoff, M; Olivi, A; Supko, JG; Ye, X | 1 |
| Fletcher, JA; Fountzilas, G; Kalebic, T; Kalogera-Fountzila, A; Karanastasi, S; Karkavelas, G; Labropoulos, S; Norris, JL; Razis, E; Selviaridis, P; Song, DD; Torrens, M; Zhu, MJ | 1 |
| Bergstrom, P; Blomquist, E; Campone, M; Clement, P; Dresemann, G; Easaw, J; Gijtenbeek, A; Gil, M; Gordower, L; Green, S; Hau, P; Nikolova, Z; Raizer, J; Reardon, DA; Schlegel, U; Schultz, H; Taillibert, S; Tonn, J; van den Bent, M; Weir, A | 1 |
| Bertolotti, A; Facoetti, A; Mariotti, L; Nano, R; Ottolenghi, A; Pasi, F; Ranza, E | 1 |
| Dresemann, G; Hasselblatt, M; Jarvius, M; Joensuu, H; Lindh, MB; Nistér, M; Nupponen, NN; Ostman, A; Paulsson, J; Paulus, W; Puputti, M; Söderberg, O; von Deimling, A | 1 |
| Beery, E; Fenig, E; Gil-Ad, I; Israeli, M; Lahav, M; Nordenberg, J; Tzadok, S; Uziel, O; Weizman, A | 1 |
| Brennan, CW; Fomchenko, EI; Fujii, K; Holland, EC; Huse, JT; Ladanyi, M; Levine, RL; Nakada, M; Oka, H; Ozawa, T; Pedraza, A; Sasayama, T; Squatrito, M; Tandon, A; Utsuki, S; Wang, L; Yasui, Y | 1 |
| Deng, Z; Dong, Y; Han, Q; Jiang, T; Jin, H; Lu, X; Ren, H; Su, J; Wang, X; Zhang, W; Zou, Y | 1 |
| Akgün, E; Avsar, T; Bayri, Y; Kılıç, T; Şeker, A; Yener, U | 1 |
| Dresemann, G | 1 |
| Altundag, K; Altundag, MB; Altundag, O; Boruban, C; Yavas, O | 1 |
| Birner, P; Budka, H; Gelpi, E; Haberler, C; Hainfellner, JA; Marosi, C; Rössler, K | 1 |
| Chiusolo, P; De Matteis, S; De Vita, S; Fiorini, A; Laurenti, L; Leone, G; Piccirillo, N; Reddiconto, G; Sica, S; Sorà, F | 1 |
| Geng, L; Hallahan, DE; Kim, D; Osusky, K; Shinohara, ET; Shyr, Y; Tan, J | 1 |
| Badruddoja, MA; Desjardins, A; Dowell, JM; Dresemann, G; Egorin, MJ; Friedman, AH; Friedman, HS; Gururangan, I; Gururangan, S; Herndon, JE; Kicielinski, KP; Lagattuta, TF; McLendon, RE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Salvado, AJ; Sampson, JH; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Bin, V; Dubois, F; Le Jeune, N; Perek, N | 1 |
| Gewirtz, DA; Quick, QA | 1 |
| Abdollahi, A; Bischof, M; Debus, J; Huber, PE; Krempien, R; Lindel, K; Lipson, KE; Milker-Zabel, S; Oertel, S; Peschke, P; Zabel, A | 1 |
| Bihorel, S; Camenisch, G; Gross, G; Lemaire, M; Scherrmann, JM | 1 |
| Boulay, JL; Egler, V; Failly, M; Imber, R; Korur, S; Lino, MM; Merlo, A | 1 |
| Amariglio, N; Gal, H; Givol, D; Makovitzki, A; Ram, Z; Rechavi, G | 1 |
| Chatzipanagiotou, T; Papantoniou, V; Pirmettis, I; Ptohis, N; Tsiouris, S | 1 |
| Abrey, LE; Gavrilovic, IT; Lassman, AB; Rosenfeld, SS; Shah, GD; Silver, JS | 1 |
| Liau, LM; Salgaller, ML | 1 |
| Acar, M; Alberta, JA; Black, PM; Buchdunger, E; Iannarelli, P; Kilic, T; O'Reilly, T; Stiles, CD; Zdunek, PR | 1 |
1 review(s) available for imatinib mesylate and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Current status of clinical trials for glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Glioblastoma; Humans; Imatinib Mesylate; Immunotoxins; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Piperazines; Polyesters; Protein Kinase Inhibitors; Proteins; Pyrimidines; Quinazolines; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Transcription Factors | 2006 |
10 trial(s) available for imatinib mesylate and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Glioblastoma; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Postoperative Care; Prognosis; Protein Kinase Inhibitors; Retreatment; Treatment Outcome | 2020 |
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Female; Glioblastoma; Glioma; Humans; Hydroxyurea; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Phthalazines; Piperazines; Pyridines; Pyrimidines; Recurrence; Treatment Outcome | 2009 |
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Brain Neoplasms; Chromatography, High Pressure Liquid; Glioblastoma; Humans; Imatinib Mesylate; Mass Spectrometry; Piperazines; Pyrimidines; Tissue Distribution | 2010 |
Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Brain Neoplasms; Extracellular Signal-Regulated MAP Kinases; Female; Glioblastoma; Humans; Imatinib Mesylate; Ki-67 Antigen; Male; Middle Aged; Neoadjuvant Therapy; Oncogene Protein v-akt; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Young Adult | 2009 |
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Brain Neoplasms; Female; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Survival Rate | 2009 |
Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Recurrence, Local; Phosphorylation; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Rate | 2011 |
Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Female; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2005 |
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis | 2005 |
Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Bone Marrow Diseases; Brain Neoplasms; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Nucleic Acid Synthesis Inhibitors; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Treatment Outcome | 2007 |
39 other study(ies) available for imatinib mesylate and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Discovery of pyrrole derivatives for the treatment of glioblastoma and chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; Glioblastoma; Heterocyclic Compounds; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methane; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Polymerization; Structure-Activity Relationship; Tubulin; Tubulin Modulators; Tumor Cells, Cultured | 2021 |
Report of Canonical
Topics: Female; Fusion Proteins, bcr-abl; Glioblastoma; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Middle Aged; Protein Kinase Inhibitors | 2021 |
Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis.
Topics: Biomarkers, Tumor; Cell-Free Nucleic Acids; Cytoskeletal Proteins; DNA, Neoplasm; Gene Fusion; Glioblastoma; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Mutation; Oncogene Proteins, Fusion; Protein-Tyrosine Kinases; Proto-Oncogene Proteins | 2022 |
Peptide-based targeted cancer therapeutics: Design, synthesis and biological evaluation.
Topics: Antineoplastic Agents; Glioblastoma; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Peptides; Protein Kinase Inhibitors; Tyrosine | 2022 |
Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Cycle Checkpoints; Cell Hypoxia; Cell Line, Tumor; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Imatinib Mesylate; Male; Metformin; Mice; Oncogene Proteins, Fusion; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Progression-Free Survival; Proto-Oncogene Protein c-fli-1; Proto-Oncogene Proteins c-akt; RNA-Binding Protein EWS; RNA-Seq; Sarcoma, Ewing; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2020 |
Differentiation of glioblastoma stem cells promoted by miR-128 or miR-302a overexpression enhances senescence-associated cytotoxicity of axitinib.
Topics: Antineoplastic Agents; Axitinib; Cell Differentiation; Cell Line, Tumor; Combined Modality Therapy; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Imatinib Mesylate; MicroRNAs; Neoplastic Stem Cells; Protein Kinase Inhibitors; Up-Regulation | 2021 |
Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Computational Biology; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Glioblastoma; Humans; Imatinib Mesylate; Microarray Analysis; Piperazines; Pyrimidines; rac1 GTP-Binding Protein; Receptors, Notch; RNA, Neoplasm; Signal Transduction; Temozolomide | 2013 |
Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cryopreservation; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gene Dosage; Glial Fibrillary Acidic Protein; Glioblastoma; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Temozolomide; Tumor Cells, Cultured; Vincristine | 2013 |
Polymerase I and transcript release factor acts as an essential modulator of glioblastoma chemoresistance.
Topics: Benzamides; Caveolin 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Humans; Imatinib Mesylate; Piperazines; Proteomics; Pyrimidines; Recurrence; RNA-Binding Proteins | 2014 |
Gleevec/imatinib, an ABL2 kinase inhibitor, protects tumor and endothelial cells from semaphorin-induced cytoskeleton collapse and loss of cell motility.
Topics: Benzamides; Cell Line, Tumor; Cell Movement; Cytoskeleton; Endothelial Cells; Glioblastoma; GTPase-Activating Proteins; Human Umbilical Vein Endothelial Cells; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Semaphorin-3A | 2014 |
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human; Cyclin-Dependent Kinase 4; Dacarbazine; Disease Progression; Fatal Outcome; Female; Genetic Association Studies; Genetic Predisposition to Disease; Glioblastoma; Humans; Imatinib Mesylate; Isocitrate Dehydrogenase; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Neurosurgical Procedures; Phenotype; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Temozolomide; Time Factors; Treatment Outcome | 2015 |
MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
Topics: 3' Untranslated Regions; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Shape; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Imatinib Mesylate; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Protein Kinase Inhibitors; RNA Interference; RNA, Neoplasm; RNA, Small Interfering; Snail Family Transcription Factors; Transcription Factors; Transfection | 2015 |
A NOX2/Egr-1/Fyn pathway delineates new targets for TKI-resistant malignancies.
Topics: Antineoplastic Agents; Brain Neoplasms; Dasatinib; Drug Resistance, Neoplasm; Early Growth Response Protein 1; ErbB Receptors; Fusion Proteins, bcr-abl; Glioblastoma; Humans; Imatinib Mesylate; Membrane Glycoproteins; NADPH Oxidase 2; NADPH Oxidases; Neoplastic Stem Cells; Oxidation-Reduction; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fyn; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Spheroids, Cellular; Tumor Cells, Cultured | 2015 |
A Thermodynamic-Based Interpretation of Protein Expression Heterogeneity in Different Glioblastoma Multiforme Tumors Identifies Tumor-Specific Unbalanced Processes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Computational Biology; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Genes, Reporter; Genetic Heterogeneity; Glioblastoma; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasm Proteins; Phosphoproteins; Signal Transduction; Thermodynamics | 2016 |
Investigation of imatinib loaded surface decorated biodegradable nanocarriers against glioblastoma cell lines: Intracellular uptake and cytotoxicity studies.
Topics: Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Glioblastoma; Humans; Imatinib Mesylate; Lactic Acid; Nanoparticles; Particle Size; Poloxamer; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2016 |
Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Movement; Crk-Associated Substrate Protein; Discoidin Domain Receptor 1; Focal Adhesion Kinase 1; Glioblastoma; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Invasiveness; Paxillin; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction | 2016 |
Antagonist activity of the antipsychotic drug lithium chloride and the antileukemic drug imatinib mesylate during glioblastoma treatment in vitro.
Topics: Antimanic Agents; Antineoplastic Agents; Apoptosis; Aquaporin 4; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclic AMP; Drug Combinations; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Imatinib Mesylate; Lithium Chloride; Multidrug Resistance-Associated Proteins; Receptor, Platelet-Derived Growth Factor alpha; Time Factors | 2016 |
Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Glioblastoma; Humans; Imatinib Mesylate; Intercellular Signaling Peptides and Proteins; Mice; Models, Biological; Neurons; Oligopeptides; Piperazines; Pyrimidines | 2008 |
MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Glycoproteins; Humans; Imatinib Mesylate; MicroRNAs; Neoplastic Stem Cells; Peptides; Piperazines; Promoter Regions, Genetic; Pyrimidines; Smad3 Protein; Smad4 Protein | 2008 |
Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Induction; Female; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Isoenzymes; Male; Middle Aged; Piperazines; Pyrimidines; Seizures; Young Adult | 2008 |
Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Neurosurgical Procedures; Piperazines; Positron-Emission Tomography; Pyrimidines | 2009 |
In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation.
Topics: Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Size; Cell Survival; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Flow Cytometry; Glioblastoma; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tetrazolium Salts; Thiazoles | 2010 |
Influence of imatinib mesylate on radiosensitivity of astrocytoma cells.
Topics: Antineoplastic Agents; Astrocytoma; Benzamides; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Dose-Response Relationship, Drug; Gamma Rays; Glioblastoma; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2009 |
In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Down-Regulation; Drug Synergism; Glioblastoma; Humans; Imatinib Mesylate; Mitogen-Activated Protein Kinases; Phenothiazines; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Psychotropic Drugs; Pyrimidines; Selective Serotonin Reuptake Inhibitors; Temozolomide | 2010 |
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas.
Topics: Amino Acid Sequence; Base Sequence; Benzamides; Gene Dosage; Gene Fusion; Gene Rearrangement; Glioblastoma; Humans; Imatinib Mesylate; Mitogen-Activated Protein Kinases; Molecular Sequence Data; Mutation; Oligodendroglioma; Phosphatidylinositol 3-Kinases; Phosphorylation; Phthalazines; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Transformation, Genetic | 2010 |
Long-term exposure to imatinib reduced cancer stem cell ability through induction of cell differentiation via activation of MAPK signaling in glioblastoma cells.
Topics: Animals; Benzamides; Cell Differentiation; Cell Line, Tumor; Cell Transformation, Neoplastic; Enzyme Activation; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Imatinib Mesylate; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplastic Stem Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Spheroids, Cellular; Time Factors | 2012 |
Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay.
Topics: Animals; Antineoplastic Agents; Benzamides; Brain; Cornea; Cranial Nerve Neoplasms; Glioblastoma; Humans; Imatinib Mesylate; Male; Neovascularization, Pathologic; Neurofibromatosis 2; Neuroma, Acoustic; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Platelet-Derived Growth Factor; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Imatinib may be useful in the management of patients with glioblastoma.
Topics: Antineoplastic Agents; Benzamides; Brain Diseases; Clinical Trials as Topic; Evidence-Based Medicine; Glioblastoma; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Radiation-Sensitizing Agents | 2005 |
Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cohort Studies; Enzyme Inhibitors; Female; Glioblastoma; Homeodomain Proteins; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Patient Selection; Piperazines; Predictive Value of Tests; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Survival Analysis | 2006 |
Imatinib for secondary Ph+ acute lymphoblastic leukemia induces response in concomitant GBM.
Topics: Adult; Antineoplastic Agents; Benzamides; Brain Neoplasms; Glioblastoma; Humans; Imatinib Mesylate; Male; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2006 |
STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blood-Brain Barrier; Brain Neoplasms; Caspase 3; Caspases; Cell Line, Tumor; Disease Models, Animal; Drug Evaluation, Preclinical; Glioblastoma; Imatinib Mesylate; Male; Mice; Mice, Nude; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines; Radiation-Sensitizing Agents; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta | 2006 |
Evaluation of imatinib mesylate effects on glioblastoma aggressiveness with SPECT radiotracer 99mTc-(v)-DMSA.
Topics: Antineoplastic Agents; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiopharmaceuticals; Receptors, Platelet-Derived Growth Factor; Technetium Tc 99m Dimercaptosuccinic Acid; Tomography, Emission-Computed, Single-Photon | 2006 |
Enhancement of radiation sensitivity, delay of proliferative recovery after radiation and abrogation of MAPK (p44/42) signaling by imatinib in glioblastoma cells.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Separation; Combined Modality Therapy; Flow Cytometry; Glioblastoma; Humans; Imatinib Mesylate; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Piperazines; Pyrimidines; Radiation-Sensitizing Agents; Signal Transduction; Time Factors | 2006 |
Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Endothelial Cells; Glioblastoma; Humans; Imatinib Mesylate; Mice; Mice, Inbred BALB C; Mice, Nude; Microcirculation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Transplantation, Heterologous; Tumor Stem Cell Assay | 2006 |
Influence of hydroxyurea on imatinib mesylate (gleevec) transport at the mouse blood-brain barrier.
Topics: Animals; Antineoplastic Agents; Benzamides; Biological Transport; Blood-Brain Barrier; Brain; Glioblastoma; Hydroxyurea; Imatinib Mesylate; Male; Mice; Mice, Inbred Strains; Piperazines; Pyrimidines; Rats; Rats, Wistar | 2006 |
Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.
Topics: Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epothilones; ErbB Receptors; Everolimus; Glioblastoma; Humans; Imatinib Mesylate; Immunosuppressive Agents; MAP Kinase Kinase 1; Microtubules; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phorbol Esters; Phosphatidylinositol 3-Kinases; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Pyrimidines; Signal Transduction; Sirolimus; Tumor Cells, Cultured | 2007 |
A rapid assay for drug sensitivity of glioblastoma stem cells.
Topics: AC133 Antigen; Anti-Infective Agents; Antigens, CD; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Glioblastoma; Glycoproteins; Humans; Imatinib Mesylate; Immunohistochemistry; Peptides; Piperazines; Pyrimidines; Stem Cells; Time Factors | 2007 |
Pentavalent technetium-99m dimercaptosuccinic acid [99m Tc-(V)DMSA] brain scintitomography--a plausible non-invasive depicter of glioblastoma proliferation and therapy response.
Topics: Adult; Antineoplastic Agents; Benzamides; Brain; Brain Neoplasms; Cell Proliferation; Fatal Outcome; Glioblastoma; Humans; Imatinib Mesylate; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Radiopharmaceuticals; Technetium Tc 99m Dimercaptosuccinic Acid; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2007 |
Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Brain Neoplasms; Cell Division; Cell Transformation, Viral; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glioblastoma; Growth Inhibitors; HeLa Cells; Humans; Imatinib Mesylate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Piperazines; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Tumor Cells, Cultured | 2000 |